The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
 
Kim Anna Reiss
Employment - Champions Oncology (I)
Stock and Other Ownership Interests - Champions Oncology (I)
Consulting or Advisory Role - Johnson & Johnson (I)
 
Joseph M. Herman
Consulting or Advisory Role - Oncosil
 
Marianna Zahurak
No Relationships to Disclose
 
Anthony W. Fyles
No Relationships to Disclose
 
Michael F. Milosevic
No Relationships to Disclose
 
Angela Scardina
No Relationships to Disclose
 
Caitlin Joffe
No Relationships to Disclose
 
Emily Petito
No Relationships to Disclose
 
Amy Hacker-Prietz
No Relationships to Disclose
 
Alice P. Chen
No Relationships to Disclose
 
Sarah Madhu Temkin
No Relationships to Disclose
 
Naomi Horiba
No Relationships to Disclose
 
Robert J. Kinders
No Relationships to Disclose
 
Lihua Wang
No Relationships to Disclose
 
Lee-Anne Stayner
No Relationships to Disclose
 
Nilofer Saba Azad
Honoraria - Merck
Consulting or Advisory Role - Dava Oncology
Research Funding - Agios (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Genentech (Inst); Kinex (Inst); Precision Biologics (Inst)
Travel, Accommodations, Expenses - Merck